Natural products have long been a treasure trove for drug discovery, with their diverse bioactivity and historical use in traditional medicine inspiring numerous clinical advancements. A recent review published in Engineering highlights the innovative research strategies behind the development of Anemoside B4 (AB4), a triterpenoidal saponin derived from Pulsatilla chinensis, which has garnered significant attention for its potent anti-inflammatory and immunomodulatory activities.

The study, led by researchers from Soochow University in China and the University of Mississippi in the USA, provides a comprehensive overview of AB4’s discovery process, emphasizing its potential as a therapeutic agent for conditions such as ulcerative colitis. AB4 has been approved for clinical trials by the National Medical Products Administration in China, marking a significant step forward in its development as a novel therapeutic.

The review details the scientific rationale behind AB4’s development, which diverges from conventional drug discovery paradigms. Instead of relying on preliminary in vitro screenings, the research prioritized direct in vivo evaluation using animal models. This approach circumvented the limitations of AB4’s low in vitro activity and addressed safety concerns associated with its injection administration. The study found that AB4 exhibited anti-inflammatory and immunomodulatory effects comparable to dexamethasone, a widely used anti-inflammatory drug, but with lower toxicity and fewer side effects.

A key challenge in AB4’s development is its high water solubility due to multiple sugar units, which limits its bioavailability and pharmacokinetic profiles. To overcome this, researchers employed structural modifications through chemical methods and enzymatic hydrolysis. These modifications resulted in derivatives with reduced molecular weight, improved bioavailability, and enhanced pharmacological activity. For instance, derivatives such as A3-6 and B4-39 demonstrated significant improvements in pharmacokinetic properties and anti-inflammatory effects in murine models of colitis.

The review also highlights AB4’s potential therapeutic applications in both veterinary and human medicine. In veterinary medicine, AB4 has shown promise in treating bovine mastitis, calf and piglet diarrhea, and canine pneumonia, with intramuscular injections proving particularly effective. In human medicine, AB4’s potential extends to the treatment of autoimmune diseases like inflammatory bowel disease (IBD), metabolic disorders such as Type II diabetes, and infectious diseases including pneumonia. Its ability to modulate key cellular targets and pathways, such as pyruvate carboxylase (PC) and the TLR4/NF-κB/MAPK signaling pathway, underscores its potential as a multi-target therapeutic agent.

Furthermore, the study explores various administration routes for AB4, including intravenous, intraperitoneal, and rectal suppositories, each offering distinct advantages in terms of bioavailability and therapeutic efficacy. For example, rectal administration significantly extended AB4’s half-life compared to oral administration, highlighting its potential for localized delivery in conditions like ulcerative colitis.

Despite these advancements, the review acknowledges several challenges that remain. These include the need for validated human safety and efficacy data, formulation challenges related to stability and scalability, and a more complete understanding of AB4’s interactions with mitochondrial targets. Future research should focus on clinical translation through investigational new drug (IND)-enabling studies and Phase I trials, as well as the development of advanced delivery systems and combination therapies.

The innovative strategies employed in the development of Anemoside B4 offer valuable insights into the discovery and optimization of natural product-derived drugs. As research progresses, AB4 and its derivatives hold promise as novel therapeutic candidates for a range of inflammatory and metabolic conditions, bridging traditional medicine with modern drug development.

The paper “Innovative Strategies in Natural Product Drug Discovery: The Case of Anemoside B4,” is authored by Naixin Kang, Jianping Zhao, Penghao Gao, Yue Lu, Zhong Chen, Xiaoran Li, Ikhlas A. Khan, Shilin Yang, Qiongming Xu, Yanli Liu. Full text of the open access paper: https://doi.org/10.1016/j.eng.2025.06.036. For more information about Engineering, visit the website at https://www.sciencedirect.com/journal/engineering.